162 related articles for article (PubMed ID: 36371419)
1. Surrogacy analysis of intermediate end-points for overall survival in randomized controlled trials of rhabdomyosarcoma.
Kubota Y; Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
Sci Rep; 2022 Nov; 12(1):19381. PubMed ID: 36371419
[TBL] [Abstract][Full Text] [Related]
2. A meta-analytic evaluation of the correlation between event-free survival and overall survival in randomized controlled trials of newly diagnosed Ewing sarcoma.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2020 May; 20(1):379. PubMed ID: 32370741
[TBL] [Abstract][Full Text] [Related]
3. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
Etekal T; Koehn K; Sborov DW; McClune B; Prasad V; Haslam A; Berger K; Booth C; Al Hadidi S; Abdallah AO; Goodman A; Mohyuddin GR
Br J Haematol; 2023 Mar; 200(5):587-594. PubMed ID: 36495317
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
5. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
Ronellenfitsch U; Jensen K; Seide S; Kieser M; Schwarzbach M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Piessen G; Schuhmacher C; Urba S; van de Velde C; Ychou M; Hofheinz R; Lorenzen S
Eur J Cancer; 2019 Dec; 123():101-111. PubMed ID: 31678767
[TBL] [Abstract][Full Text] [Related]
6. Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Matsuda S; Itonaga I; Tsumura H
Sci Rep; 2020 May; 10(1):8573. PubMed ID: 32444660
[TBL] [Abstract][Full Text] [Related]
7. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Berry D; Clarke N; Collette L; D'Amico A; Lourenco RA; Dignam J; Eisenberger M; James N; Fizazi K; Gillessen S; Loriot Y; Mottet N; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ;
J Clin Oncol; 2020 Sep; 38(26):3032-3041. PubMed ID: 32552276
[TBL] [Abstract][Full Text] [Related]
8. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.
Korn EL; Sachs MC; McShane LM
Ann Oncol; 2016 Jan; 27(1):10-5. PubMed ID: 26489443
[TBL] [Abstract][Full Text] [Related]
9. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
10. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
Hua T; Gao Y; Zhang R; Wei Y; Chen F
BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
[TBL] [Abstract][Full Text] [Related]
11. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
Shi Q; Schmitz N; Ou FS; Dixon JG; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Habermann TM; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Coiffier B; Flowers CR
J Clin Oncol; 2018 Sep; 36(25):2593-2602. PubMed ID: 29975624
[TBL] [Abstract][Full Text] [Related]
12. Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting.
Wainberg ZA; Xie J; Valderrama A; Yin L; Zhang S; Shih CS; Bhagia P; Gu Q; Shitara K; Janjigian YY; Tabernero J
Clin Cancer Res; 2023 Apr; 29(7):1360-1367. PubMed ID: 36652563
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma.
Liu H; Wang Y; Qi C; Xie T; Peng Z; Li J; Shen L; Zhang X
Front Oncol; 2022; 12():835389. PubMed ID: 35463354
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
[TBL] [Abstract][Full Text] [Related]
15. Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.
Colloca G; Venturino A
Med Oncol; 2017 May; 34(5):87. PubMed ID: 28391579
[TBL] [Abstract][Full Text] [Related]
16. Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer.
Liang F; Zhang S; Wang Q; Li W
Crit Rev Oncol Hematol; 2018 Oct; 130():36-43. PubMed ID: 30196910
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Randomized Trials in Advanced/Metastatic Soft Tissue Sarcoma: End Point Selection, Surrogacy, and Quality of Reporting.
Zer A; Prince RM; Amir E; Abdul Razak A
J Clin Oncol; 2016 May; 34(13):1469-75. PubMed ID: 26951308
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points.
Lee L; Wang L; Crump M
Ann Oncol; 2011 Jun; 22(6):1392-1403. PubMed ID: 21266519
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P
Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]